secwatch.observer — SEC 8-K summary
======================================

Issuer:     IO Biotech, Inc. (IOBTQ)
CIK:        0001865494
Form:       8-K
Filed at:   2023-05-11T23:59:59+00:00
Accession:  0001193125-23-142000
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

IO Biotech reports Q1 net loss of $17.0M; Phase 3 melanoma trial on track for mid-2023 enrollment milestone
--------------------------------------------------------------------------------

- Net loss $17.0M for Q1 2023, nearly flat vs $17.2M in Q1 2022.
- Cash and equivalents $128.5M as of March 31, 2023; expected to fund operations through Q3 2024.
- Phase 3 pivotal trial (IOB-013) in advanced melanoma: expects 225 patients randomized by mid-2023, full enrollment by end of 2023.
- Phase 2 basket trial (IOB-022) in lung cancer: 4 partial responses, 4 stable disease among 9 evaluable patients; safety consistent.
- FDA cleared IND for IO102-IO103 in neo-adjuvant/adjuvant solid tumors; Phase 2 trial to start H2 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1865494/000119312523142000/0001193125-23-142000-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1865494/000119312523142000/d471457d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-142000

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer